IPS is a leading provider of Technical Consulting, Design, Engineering, Construction, Project Controls, Commissioning and Qualification services for technically complex facilities worldwide.
Integrated Project Services (IPS)
721 Arbor Way, Suite 100
Blue Bell, PA 19422
IPS-Integrated Project Services, ULC, a leading provider of Engineering, Procurement, Construction Administration and Validation (EPCAV) services, was selected by BWXT ITG Canada, Inc. to provide Basis of Design and Detailed Design for BWX Technologies, Inc.'s (BWXT) isotope project, specifically the expansion of their medical isotope and radiopharmaceutical facility in Ottawa, Ontario, Canada.
ENR's Global Best Projects identifies and honors the project teams behind outstanding design and construction efforts of the past year. They received a record number of entries produces a diverse set of projects located in 20 countries that focused on safety performance, innovations, challenges, and design and construction quality - with a special emphasis on the diversity of global project teams and their collaboration.
IPS-Integrated Project Services, LLC (IPS), a leading provider of Engineering, Procurement, Construction Management and Validation (EPCMV) services, announces the ninth annual IPS Technologies Tours at INTERPHEX with Tours focused on the hottest trends in the industry, including Pharma 4.0 concepts, cell processing, and gene therapy.
Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the sixth in a six-part series on how single-use systems (SUS) are changing the modern biotechnology facility design and construction paradigm.
Cell therapies have the potential to revolutionize the biopharmaceutical world, but today’s processes, logistics, and delivery make for a challenging entry into the sector’s growth curve. As the industry evolves, we have to answer (at least) three important questions when bringing these exciting new therapies to market.
In 1931, Swiss doctor Paul Niehans injected a preparation of live cells from a parathyroid gland into a dying patient. The patient subsequently recovered, and Dr. Niehans had a eureka moment — that injections of living cells can have tremendous therapeutic value.
Pharmaceutical plants cannot be treated like real estate. Instead, they require a detailed assessment of where they are in “operational compliance and production readiness.”
In part 1 of our article on biocontainment, we discussed the history of biocontainment as an outgrowth of medical research, especially the effort to develop vaccines for various worldwide diseases. We provided some definition of the biosafety levels (BSLs) established by the Centers for Disease Control and Prevention (CDC) based on risk considerations. We also discussed the regulatory regime for biological agents and, specifically, for designing a facility for an FDA or EU regulated product within the confines of the safety practices dictated by the CDC and design requirements of the NIH.
Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the third in a six-part series on how single-use systems are changing the modern biotechnology facility and process design paradigm.
This article explores modern facility design principles that make use of the most flexible new technologies and provide a platform to rein in costs, reduce schedules, and deliver products compliantly and within business risk tolerance.
Today’s disposable systems offer improved manufacturing efficiency, and better QA and regulatory compliance — and they can be the fastest route to media fills
The movement of viral vectors, cell therapies and other antibody-based next-generation drug products toward commercialization is driving the need for new and different technologies and facilities. Engineering and design firms with the right skill sets can help you maintain the right balance in your facility design to maintain flexibility which is essential to meet diverse processing needs for biopharmaceutical manufacturing.
IPS-Integrated Project Services, LLC and G-CON Manufacturing, Inc. announced recently that the iCON™ product portfolio now has a second manufacturing site in Kilkenny, Ireland, through the Manufacturing and Supply Agreement between G-CON and Asgard Cleanroom Solutions Ltd.
IPS-Integrated Project Services, LLC (IPS), a leading global provider of engineering, architecture, project controls, construction management, commissioning and qualification services, and G-CON Manufacturing, Inc. the leading provider of prefabricated cleanrooms, announced the unveiling of the iCON™ brand which represents the collective facility design and build capabilities of the two companies.